CClinicalTrials.gg
Active, not recruitingNCT04062552Updated Jan 13, 2026

Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers

An interventional study of Behavioral, Psychological or Informational Intervention and Educational Intervention in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm and Recurrent Malignant Solid Neoplasm, sponsored by University of Rochester NCORP Research Base. Active, not recruiting at 113 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University of Rochester NCORP Research Base · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial studies the delivery of the ENABLE palliative care program by two different methods called a Virtual Learning Collaborative or Technical Assistance for patients with advanced cancer and their caregivers. Palliative care is specialized medical care for people with a serious illness that occurs at the same time as other medical treatment. The purpose of palliative care is to provide relief from symptoms and stress of serious illness, to help patients and their families clarify goals of care, and to focus on social support and spiritual well-being. The focus of the ENABLE palliative care program is on living well, managing stress, patient communication of their personal values and hopes for care, social support, and symptom management. This study may help doctors find the best ways to include palliative care services into their practices and the impact of palliative care on cancer patients and their caregivers' quality of life.

Read the detailed description

PRIMARY OBJECTIVE:

I. Gather preliminary data on the effectiveness of virtual learning collaborative (VLC) versus (vs.) technical assistance (TA) on educate, nurture, advise before life ends (ENABLE) program uptake, defined as the proportion of patients that complete a palliative care assessment and at least 4 ENABLE sessions.

SECONDARY OBJECTIVE:

I. Evaluate the preliminary effectiveness of VLC or TA on patient quality of life (QOL) and mood outcomes.

II. Evaluate the relationship between ENABLE program uptake and patients' QOL and mood across the two strategies.

EXPLORATORY OBJECTIVES:

I. Evaluate the effectiveness of VLC vs. TA on participating institutions' overall ENABLE program implementation, as measured by the General Organizational Index (GOI).

II. Evaluate the relationship between overall ENABLE program implementation and patients' QOL and mood across the two strategies.

OUTLINE: Health care practice sites are randomized to 1 of 2 groups.

GROUP I: Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with an ENABLE coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with an ENABLE coach and monthly follow-up calls for 6 months. The practice sites participate in a Virtual Learning Collaborative (VLC) consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for 15 months.

GROUP II: Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with an ENABLE coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with an ENABLE coach and monthly follow-up calls for 6 months. The practice sites undergo practice-based consultation calls with an ENABLE/Technical Assistance (TA) expert monthly for 15 months.

After completion of the study, participants are followed up at 12 and 24 weeks.

02

Conditions studied

  • Advanced Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • Recurrent Malignant Solid Neoplasm

Browse trials for

03

In context

Neoplasm Metastasis

3,517 studies on the registry are indexed under Neoplasm Metastasis; 885 are open to participants now.

This study's planned enrollment of 208 is above the median of 54 across 2,767 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

University of Rochester NCORP Research Base is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • PRACTICE SITE: All participating practice clusters will be asked to identify one (or more) ENABLE coach as part of study eligibility to deliver the ENABLE program.
  • PRACTICE SITE: Commitment of the ENABLE coach(es) to be trained to conduct the palliative care assessment (and ENABLE sessions if the practice plans to implement them).
  • PRACTICE SITE: Desire to implement ENABLE, including presence of an investigator (e.g., primary affiliate principal investigator [PI], oncology physician, Cancer Care Delivery Research [CCDR] Lead) and/or program administrator/supervisor who are willing to be key contacts.
  • PRACTICE SITE: Demonstrated support/buy-in from oncology physicians who are willing to enroll patients.
  • PRACTICE SITE: Agreement of practice leadership and other individuals at the practice cluster to support/participate in the study activities.
  • PRACTICE SITE: If necessary, willingness to participate in a phone interview to determine capacity to implement the ENABLE program.
  • INDIVIDUALS AT THE PARTICIPATING PRACTICE: The ENABLE implementation team at each participating practice will include at minimum one ENABLE coach and a coordinator. Other members of the team can include the primary affiliate PI, an oncology physician or investigator, CCDR lead (if different than the coordinator, and/or the program administrator/supervisor) and other professional individuals.
  • ONCOLOGY PHYSICIAN: Eligible providers at practices sites are oncology physicians (i.e., medical oncologists or radiation oncologists including trainees) caring for oncology patients. If no oncology physicians are available at the practice, other providers (e.g., advanced practice providers [APPs]) may take on the responsibilities of the oncology physician as laid out in this protocol. We do not require that all physicians at a practice setting agree to participate. Oncology physicians must work at a participating practice cluster with no plans to leave that practice site or retire at the time of enrollment into the study. Physicians (oncologists) may serve in the ENABLE coach role and perform the palliative care assessment, ENABLE sessions and/or monthly follow-up calls per practice discretion if they have completed appropriate training.
  • ENABLE COACH: All participating practice clusters will be required to identify one (or more) ENABLE coaches as part of study eligibility to deliver the ENABLE program. The ENABLE coach is responsible for ensuring the ENABLE sessions and follow-up calls are completed per protocol specifications.
  • ENABLE COACH: A registered nurse or advanced practice provider (including a nurse practitioner or physician assistant), a physician (e.g., medical and radiation oncologists, including oncology trainees), or other professionals (e.g., social workers, chaplains) with appropriate credentials and experience to deliver ENABLE
  • ENABLE COACH: Individuals with an appropriate clinical license (i.e., a registered nurse, advanced practice provider, or physician, as defined above) may perform the palliative care assessment and any ENABLE sessions and follow-up calls the practice chooses to deliver
  • ENABLE COACH: Other professionals (e.g., social workers, chaplains) may deliver ENABLE sessions and monthly follow-up calls for which their credentials and experience are appropriate
  • ENABLE COACH: ENABLE coaches complete appropriate study training for any content delivered.
  • PATIENTS: English-speaking as not all patient measures have been validated in other languages.
  • PATIENTS: Age >= 18
  • PATIENTS: Willing to complete palliative care assessment and ENABLE sessions.
  • PATIENTS: Diagnosed within the last 90 days with an advanced cancer (defined as a newly diagnosed stage III/IV, recurrence, or progressive solid tumor cancer). Patients can receive any cancer treatment for their advanced cancer while participating in this study.

    • The 90-day interval refers to when the patient was made aware of their diagnosis.
  • PATIENTS: Expected survival of at least 6 months.
  • PATIENTS: Have access to telephone that can receive incoming calls.
  • PATIENTS: Able to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • PATIENTS: Received previous palliative care services. (Concurrent palliative care is allowed.)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    Group I (ENABLE palliative care program, phone calls, VLC)

    Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with an ENABLE coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with an ENABLE coach and monthly follow-up calls for 6 months. The practice sites participate in a VLC consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for 15 months.

    Other: Behavioral, Psychological or Informational Intervention · Other: Educational Intervention · Procedure: Medical Examination Assessment · Other: Quality-of-Life Assessment · Other: Survey Administration · Behavioral: Telephone-Based Intervention

  • Experimental
    Group II (ENABLE palliative care program, phone calls, TA)

    Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with an ENABLE coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with an ENABLE coach and monthly follow-up calls for 6 months. The practice sites undergo practice-based consultation calls with an ENABLE/TA expert monthly for 15 months.

    Other: Behavioral, Psychological or Informational Intervention · Other: Educational Intervention · Procedure: Medical Examination Assessment · Other: Quality-of-Life Assessment · Other: Survey Administration · Behavioral: Telephone-Based Intervention

Interventions

  • OtherBehavioral, Psychological or Informational Intervention

    Receive ENABLE palliative care information

  • OtherEducational Intervention

    Participate in VLC group-based learning sessions

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherEducational Intervention

    Participate in consultation with ENABLE/TA expert

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • ProcedureMedical Examination Assessment

    Undergo palliative care assessment

    Also known as: Exam, Examination, Health Assessment, Health Examination, Health Status Assessment, Medical Assessment, Medical Exam, Medical Inspection

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherSurvey Administration

    Complete surveys

  • BehavioralTelephone-Based Intervention

    Receive monthly phone calls

06

What researchers measure

Primary outcomes

  1. Patient completion of the Educate, Nurture, Advise, Before Life Ends (ENABLE) program

    Defined as having a palliative care assessment and completing at least 4 ENABLE sessions. A logit generalized estimating equation model with exchangeable correlation structure (to account for clustering within practice) will be fitted to a binary patient uptake indicator ("yes" if the patient completed a palliative care assessment and at least 4 ENABLE program sessions and "no" if the patient does not), with the group assignment as the main predictor. Model-predicted uptake proportions, odds ratios, relative risks, and confidence intervals for these measures will be used for interpretation. An additional analysis with sex, group assignment, and an interaction between the two as predictors will be conducted to examine whether this biological variable is a possible moderator of ENABLE program uptake.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Preliminary effectiveness of VLC or TA on patient quality of life and mood outcomes

    Will examine and quantify study group differences. A primary analysis, including all patients (either deceased or surviving by the scheduled 24-week follow-up) will be conducted using joint-modeling for longitudinal and time-to-event data to obtain inferences on the longitudinal outcome corrected for non-ignorable missing data due to death. In this approach, submodels for both the longitudinal process and the time-to-event process are estimated simultaneously, with a Cox model for the survival submodel, and a linear mixed-effects model for the longitudinal submodel. The two submodels share random effects for each individual, and these random effects account for both the association between the longitudinal outcome and the risk of death. A sensitivity analysis will also be performed.

    Time frame: At 24 weeks

  2. Relationship between ENABLE program uptake and patient outcomes

    Will estimate the relationship between change in patient outcomes (quality of life and mood) using the number of ENABLE sessions completed (ENABLE program uptake) as the main predictor. The crude association between ENABLE sessions and change in patient outcomes will be examined graphically with profile plots, and with linear mixed models to determine whether the relationship is better fitted by a linear, a more complex trend, or as ordinal categorical data. Since the number of ENABLE sessions completed might be dependent on patient characteristics (e.g., sex, illness acuity, age), a covariate adjustment (via an adjusting score) will be conducted on the crude association estimate to determine the change in outcomes attributable to the number of ENABLE sessions completed, above and beyond patient characteristics. The adjusting score will be estimated with a random forest ensemble, based on patient characteristics.

    Time frame: Up to 24 weeks

07

Study locations

113 sites
  • Mercy Hospital Fort Smith
    Fort Smith, Arkansas 72903, United States
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Island Urology-Hilo
    Hilo, Hawaii 96720, United States
  • Hawaii Cancer Care Inc - Waterfront Plaza
    Honolulu, Hawaii 96813, United States
  • Island Urology
    Honolulu, Hawaii 96813, United States
  • Queen's Cancer Cenrer - POB I
    Honolulu, Hawaii 96813, United States
  • Queen's Medical Center
    Honolulu, Hawaii 96813, United States
  • Straub Clinic and Hospital
    Honolulu, Hawaii 96813, United States
  • University of Hawaii Cancer Center
    Honolulu, Hawaii 96813, United States
  • Hawaii Cancer Care Inc-Liliha
    Honolulu, Hawaii 96817, United States
  • Kuakini Medical Center
    Honolulu, Hawaii 96817, United States
  • Queen's Cancer Center - Kuakini
    Honolulu, Hawaii 96817, United States
  • The Cancer Center of Hawaii-Liliha
    Honolulu, Hawaii 96817, United States
  • Kapiolani Medical Center for Women and Children
    Honolulu, Hawaii 96826, United States
  • Wilcox Memorial Hospital and Kauai Medical Clinic
    Lihue, Hawaii 96766, United States
  • Hawaii Cancer Care - Westridge
    ‘Aiea, Hawaii 96701, United States
  • Pali Momi Medical Center
    ‘Aiea, Hawaii 96701, United States
  • Queen's Cancer Center - Pearlridge
    ‘Aiea, Hawaii 96701, United States
  • The Cancer Center of Hawaii-Pali Momi
    ‘Aiea, Hawaii 96701, United States
  • Saint Mary's Hospital
    Centralia, Illinois 62801, United States
  • SSM Health Good Samaritan
    Mount Vernon, Illinois 62864, United States
  • Mercy Medical Center - Des Moines
    Des Moines, Iowa 50314, United States
  • Mercy Medical Center
    Springfield, Massachusetts 01104, United States
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Ann Arbor, Michigan 48106, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Brighton, Michigan 48114, United States
  • Trinity Health Medical Center - Brighton
    Brighton, Michigan 48114, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Canton
    Canton, Michigan 48188, United States
  • Trinity Health Medical Center - Canton
    Canton, Michigan 48188, United States
  • Caro Cancer Center
    Caro, Michigan 48723, United States
  • Chelsea Hospital
    Chelsea, Michigan 48118, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
    Chelsea, Michigan 48118, United States
  • Hematology Oncology Consultants-Clarkston
    Clarkston, Michigan 48346, United States
  • Newland Medical Associates-Clarkston
    Clarkston, Michigan 48346, United States
  • Henry Ford Health Saint John Hospital
    Detroit, Michigan 48236, United States
  • Henry Ford River District Hospital
    East China, Michigan 48054, United States
  • Cancer Hematology Centers - Flint
    Flint, Michigan 48503, United States
  • Genesee Hematology Oncology PC
    Flint, Michigan 48503, United States
  • Genesys Hurley Cancer Institute
    Flint, Michigan 48503, United States
  • Hurley Medical Center
    Flint, Michigan 48503, United States
  • Henry Ford Saint John Hospital - Academic
    Grosse Pointe Woods, Michigan 48236, United States
  • Henry Ford Saint John Hospital - Breast
    Grosse Pointe Woods, Michigan 48236, United States
  • Henry Ford Saint John Hospital - Van Elslander
    Grosse Pointe Woods, Michigan 48236, United States
  • University of Michigan Health - Sparrow Lansing
    Lansing, Michigan 48912, United States
  • Hope Cancer Clinic
    Livonia, Michigan 48154, United States
  • Trinity Health Saint Mary Mercy Livonia Hospital
    Livonia, Michigan 48154, United States
  • Henry Ford Saint John Hospital - Macomb Medical
    Macomb, Michigan 48044, United States
  • Henry Ford Warren Hospital - Breast Macomb
    Macomb, Michigan 48044, United States
  • Saint Mary's Oncology/Hematology Associates of Marlette
    Marlette, Michigan 48453, United States
  • Hope Cancer Center
    Pontiac, Michigan 48341, United States
  • Michigan Healthcare Professionals Pontiac
    Pontiac, Michigan 48341, United States
  • Newland Medical Associates-Pontiac
    Pontiac, Michigan 48341, United States
  • Trinity Health Saint Joseph Mercy Oakland Hospital
    Pontiac, Michigan 48341, United States
  • Henry Ford Rochester Hospital
    Rochester Hills, Michigan 48309, United States
  • MyMichigan Medical Center Saginaw
    Saginaw, Michigan 48601, United States
  • Oncology Hematology Associates of Saginaw Valley PC
    Saginaw, Michigan 48604, United States
  • Bhadresh Nayak MD PC-Sterling Heights
    Sterling Heights, Michigan 48312, United States
  • MyMichigan Medical Center Tawas
    Tawas City, Michigan 48764, United States
  • Advanced Breast Care Center PLLC
    Warren, Michigan 48088, United States
  • Henry Ford Health Warren Hospital
    Warren, Michigan 48093, United States
  • Henry Ford Madison Heights Hospital - Breast
    Warren, Michigan 48093, United States
  • Henry Ford Warren Hospital - GLCMS
    Warren, Michigan 48093, United States
  • Macomb Hematology Oncology PC
    Warren, Michigan 48093, United States
  • Saint Mary's Oncology/Hematology Associates of West Branch
    West Branch, Michigan 48661, United States
  • Huron Gastroenterology PC
    Ypsilanti, Michigan 48106, United States
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    Ypsilanti, Michigan 48197, United States
  • Mercy Clinic-Rolla-Cancer and Hematology
    Rolla, Missouri 65401, United States
  • Mercy Hospital Springfield
    Springfield, Missouri 65804, United States
  • Mercy Hospital South
    St Louis, Missouri 63128, United States
  • Mercy Hospital Saint Louis
    St Louis, Missouri 63141, United States
  • Northwell Health/Center for Advanced Medicine
    Lake Success, New York 11042, United States
  • Strecker Cancer Center-Belpre
    Belpre, Ohio 45714, United States
  • Adena Regional Medical Center
    Chillicothe, Ohio 45601, United States
  • Mount Carmel East Hospital
    Columbus, Ohio 43213, United States
  • Columbus Oncology and Hematology Associates Inc
    Columbus, Ohio 43214, United States
  • Riverside Methodist Hospital
    Columbus, Ohio 43214, United States
  • Grant Medical Center
    Columbus, Ohio 43215, United States
  • The Mark H Zangmeister Center
    Columbus, Ohio 43219, United States
  • Mount Carmel Health Center West
    Columbus, Ohio 43222, United States
  • Doctors Hospital
    Columbus, Ohio 43228, United States
  • Delaware Health Center-Grady Cancer Center
    Delaware, Ohio 43015, United States
  • Grady Memorial Hospital
    Delaware, Ohio 43015, United States
  • Dublin Methodist Hospital
    Dublin, Ohio 43016, United States
  • Central Ohio Breast and Endocrine Surgery
    Gahanna, Ohio 43230, United States
  • Mount Carmel Grove City Hospital
    Grove City, Ohio 43123, United States
  • Fairfield Medical Center
    Lancaster, Ohio 43130, United States
  • OhioHealth Mansfield Hospital
    Mansfield, Ohio 44903, United States
  • Marietta Memorial Hospital
    Marietta, Ohio 45750, United States
  • OhioHealth Marion General Hospital
    Marion, Ohio 43302, United States
  • Knox Community Hospital
    Mount Vernon, Ohio 43050, United States
  • Licking Memorial Hospital
    Newark, Ohio 43055, United States
  • Newark Radiation Oncology
    Newark, Ohio 43055, United States
  • Southern Ohio Medical Center
    Portsmouth, Ohio 45662, United States
  • Saint Ann's Hospital
    Westerville, Ohio 43081, United States
  • Genesis Healthcare System Cancer Care Center
    Zanesville, Ohio 43701, United States
  • Lehigh Valley Hospital-Cedar Crest
    Allentown, Pennsylvania 18103, United States
  • Lehigh Valley Hospital - Muhlenberg
    Bethlehem, Pennsylvania 18017, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Pocono Medical Center
    East Stroudsburg, Pennsylvania 18301, United States
  • Lehigh Valley Hospital-Hazleton
    Hazleton, Pennsylvania 18201, United States

Showing the first 100 of 113 sites.

08

References and documents

Publications

  • Zubkoff L, Carpenter-Song E, Lyons KD, Odom JN, Khalidi S, Azuero A, Flannery M, Taylor R, Richards J, Mustian K, Wells M, Hancock J, Wojtowicz M, Weiss M, Mohile S, Bakitas MA. A process evaluation of early palliative care implementation in the National Cancer Institute Community Oncology Research Program. JNCI Cancer Spectr. 2026 Mar 3;10(2):pkag018. doi: 10.1093/jncics/pkag018. PubMed 41761561 ↗
  • Zubkoff L, Lyons KD, Dionne-Odom JN, Hagley G, Pisu M, Azuero A, Flannery M, Taylor R, Carpenter-Song E, Mohile S, Bakitas MA. A cluster randomized controlled trial comparing Virtual Learning Collaborative and Technical Assistance strategies to implement an early palliative care program for patients with advanced cancer and their caregivers: a study protocol. Implement Sci. 2021 Mar 11;16(1):25. doi: 10.1186/s13012-021-01086-3. PubMed 33706770 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04062552
Lead sponsor
University of Rochester NCORP Research Base
Collaborators
National Cancer Institute (NCI)
Responsible party
Supriya Mohile (URCC Study Co-Chair, University of Rochester NCORP Research Base) — Principal investigator
First posted
Aug 20, 2019
Start date
Mar 9, 2021
Primary completion
Sep 16, 2025
Completion
Aug 23, 2026 (estimated)
Last update
Jan 13, 2026

Study contacts

Lisa Zubkoff, PhD
principal investigator · University of Rochester NCORP Research Base

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion